✦ LIBER ✦

Treatment of aggressive Non-Hodgkin's lymphoma in the elderly

✍ Scribed by Nicolas Novitzky; Helen S. King; Carol Johnson; Peter Jacobs

Publisher: John Wiley and Sons
Year: 1995
Tongue: English
Weight: 643 KB
Volume: 49
Category: Article
ISSN: 0361-8609
DOI: 10.1002/ajh.2830490202

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of non-Hodgkin's lymphoma in t

Treatment of non-Hodgkin's lymphoma in the elderly: an update

✍ Umberto Tirelli; Vittorina Zagonel; Domenico Errante; Lucia Fratino; Silvio Monf 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 166 KB 👁 2 views

Recent studies specifically directed toward assessing the outcome of older patients with non-Hodgkin's lymphoma (NHL) indicate that age per se is an important and independent prognostic factor for response and survival. We report a review of the clinical trials of the literature and the Aviano Group

The treatment of non-Hodgkin's lymphoma

✍ Samuel Hellman; David S. Rosenthal; William C. Moloney; John T. Chaffey 📂 Article 📅 1975 🏛 John Wiley and Sons 🌐 English ⚖ 432 KB 👁 2 views

Much of the approach to evaluation and management of the non-Hodgkin's lymphomas has been modeled after Hodgkin's disease. However, as the name implies, they are quite different. The non-Hodgkin's lymphomas are a group of diseases and syndromes. These many different presentations, syndromes, and pos

Treatment of aggressive non-hodgkin's ly

Treatment of aggressive non-hodgkin's lymphomas: Lessons from the past 10 years

✍ Richard I. Fisher 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 538 KB

Therapy for aggressive non-Hodgkin's lymphomas has undergone significant evolution in the last 25 years. First generation combination chemotherapy studies produced complete remissions (CRs) of 45-53%, with 30-37% long term survivors. New treatment programs aimed at increasing CR rates were then deve

Mitoxantrone, prednimustine, and vincris

Mitoxantrone, prednimustine, and vincristine for elderly patients with aggressive non-Hodgkin's lymphoma

✍ Yau, Jonathan C.; Germond, Colin; Gluck, Stefan; Cripps, Christine; Verma, Shail 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 41 KB 👁 2 views

Elderly patients with intermediate-or high-grade non-Hodgkin's lymphoma have a worse outcome than those who are younger than 60 years. It has been shown that aggressive combination chemotherapy is poorly tolerated in older patients resulting in a subsequent decrease in dose intensity. A phase II tri

The management of early-stage aggressive

The management of early-stage aggressive non-Hodgkin's lymphoma

✍ Professor A. Horwich; C. N. Catton; M. Quigley; D. Easton; M. Brada 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 481 KB

Sixty-one patients with stage I or I1 non-Hodgkin's lymphoma of aggressive histological subtype were treated at The Royal Marsden Hospital between 1972 and 1984. The overall 5-year survival probability was 69 per cent (60 per cent continuously relapse-free). The 5-year survival probability was 80 pe

Treatment of an aggressive non-Hodgkin's

Treatment of an aggressive non-Hodgkin's lymphoma during pregnancy with MACOP-B chemotherapy

✍ Nantel, Stephen ;Parboosingh, John ;Poon, Man-Chiu 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 249 KB

## Abstract Non‐Hodgkin's lymphoma occurring during pregnancy is a rare event. A young woman at 18 weeks gestation with twins presented with a B‐cell immunoblastic lymphoma. Combination chemotherapy with methotrexate, DO xorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin (MACOP‐B)